The development of facile, accurate, and affordable assays
for
microRNAs (miRNAs) in early cancer is greatly desirable but encounters
an obstacle due to low cellular abundance in biofuids. In this study,
we present a novel approach called a light-triggered exponential amplification strategy
coupled with a CRISPR/Cas13a-based diagnostic
system (LEXPA-CRISPR), which directly transduces rare miRNA targets
into photocontrolled signal enhancement response. This innovative
platform leverages trans-cleavage of CRISPR/Cas13a, activated by the
miRNA target, to cleave specific RNA fragments within the MB@PC-NAC
assembly, thus releasing free PC-single-stranded DNA (PC-ssDNA) that
is modified by a photocleavable linker (PC linker). UV irradiation
is further employed toward the photoresponsive PC-ssDNA, resulting
in instantaneous generation of oligo with a new 5′ phosphate
group (Pho-ssDNA). The Pho-ssDNA serves as a trigger for rolling circle
amplification (RCA) reaction, which generates thousands of long ssDNA
repeats of diverse lengths with a strong fluorescence signal. Through
optimization, we achieved a detection limit of 1 fM for miR21 without
the need for target amplification. Moreover, the programmable versatility
of LEXPA-CRISPR is also demonstrated for miR17 determination only
with simple modification of CRISPR RNA (crRNA) sequences. This proposed
biosensor successfully monitored the levels of miR21 and miR17 in
tumor cells, showing a satisfactory consistency with the standard
qRT-PCR method. Conclusively, LEXPA-CRISPR represents a promising
strategy for ultrasensitive miRNA detection. It combines the advantages
of light-triggered signal amplification and robust collateral cleavage
activity of Cas13a, making it an attractive tool for practical CRISPR-based
diagnostics.